Tiziana Life Sciences Ltd

TLSA·NasdaqCM·Healthcare
Compare
0.6380−0.0521 (−7.55%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close0.6901
Open0.7000
Day range0.62110.7054
52-week range0.62001.9000
Off day high−9.55%
Off 52-week high−66.42%
Volume420.92K
Avg. volume (3M)784.61K
Market cap81.19M
EPS (TTM)-0.2100
Forward P/E-3.50
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.46
Shares outstanding127.26M
Short interest7.67% of float
Earnings dateJun 23, 2025 (est.)
Analyst target8.1484
Profit margin0.00%

Against its peers

Compare in full ›
TLSA ZURA TVGN ACTI.ST IMUX CHRS
Market cap 81.19M 387.23M 95.87M 102.54M 108.34M 131.36M
P/E (TTM) — — — — — —
Forward P/E -3.5 -5.9 — — -3.4 -1.3
Price/book -30.4 2.2 -1.4 2.8 0.8 2.2
Dividend yield — — — — — —
1-year change −62.50% +15.52% −75.61% −34.67% +13.27% −42.95%
Today −7.55% +0.75% −3.38% +5.71% +4.47% +5.54%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All TLSA news ›
markets.businessinsider.com··2 outletsPositive

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ... Tiziana Life Sciences Announces…

More from 1 other outlet
markets.businessinsider.com··2 outletsPositive

Tiziana Life Sciences doses last patient in foralumab trial

Tiziana Life Sciences (TLSA) announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial evalu... Tiziana Life Sciences doses last patient in foralumab trial Tiziana Life Sciences (TLSA)…

More from 1 other outlet

From the 4Search news index, newest first.

In the news

12mentions in 30 days
9with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance